13 Oct 2020 Similarly, in March 2019, Insera Therapeutics, Inc. received Conformité Européenne (CE) Mark approval for its flagship product, the CLEAR

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney

Find out more about Insera Therapeutics Inc. including the VentureRadar Innovation and Growth scores, Similar Companies and more. Insera Therapeutics has announced that it has received CE mark approval for its flagship product, the CLEAR Aspiration System, for the aspiration of blood clots, and is indicated for use in patients with acute ischaemic stroke secondary to intracranial large vessel occlusive disease, secondary to cerebral venous sinus thrombosis, and optionally for staged aspiration through a balloon guide or SACRAMENTO, Calif.--(BUSINESS WIRE)-- Insera Therapeutics, Inc., has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $221,700 to conduct research and development (R&D) work on its flagship solution for ischemic stroke, which includes the CLEAR ® Aspiration System and the thrombectomy-assist device SHELTER ® Retriever. 2019-12-03 SBIR Phase I: Development of a textile-based retrievable stent for stroke that can be personalized to a patient's clot burden and retrieve long clots using torsion. Insera Therapeutics has announced that the first two ischaemic stroke patients have been treated with its flagship cyclic aspiration system, CLEAR. The company received CE mark approval for its flagship product, the CLEAR Aspiration System, in March 2019. Assignee: Insera Therapeutics, Inc. Inventors: Vallabh Janardhan, Vikram Janardhan Distal embolic protection devices with a variable thickness microguidewire and methods for their use Insera Therapeutics Inc. edit cover image.

Insera therapeutics

SACRAMENTO, Calif.--(BUSINESS WIRE)-- Insera Therapeutics, Inc., has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $221,700 to conduct research and development (R&D) work on its flagship solution for ischemic stroke, which includes the CLEAR ® Aspiration System and the thrombectomy-assist device SHELTER ® Retriever. Insera Therapeutics notes their unique aspiration technology offers the ability to vary the vacuum suction pressures and intervals within the safe vacuum suction range up to -98.2 kPa (-29 inHg). reports latest medical device, biotech, diagnostic executives on the move and more About Insera - Insera Therapeutics, Inc. is an ISO 13485 certified medical device company focused on treatments for vascular diseases including stroke. CLEAR TM stands for Cyclical, Luminal Vikram Janardhan started Insera Therapeutics LLC six months ago in Sacramento to develop Shelter and other stroke-treatment technologies. The company is looking for $1.1 million in seed funding. It would use the money to develop five sizes of the prototype, which will fit into blood vessels from 2.5 millimeters to 5 millimeters wide. Insera Therapeutics has announced that the first two ischaemic stroke patients have been treated with its flagship cyclic aspiration system, CLEAR.

31 May 2010 Vikram Janardhan, CEO, Insera Therapeutics; and Cary Adams, founder of, Proximal Ventures. After four quarters of increasing venture

The control system includes a microcontroller, an antenna configured to receive a signal, and a pump control About Insera: Insera Therapeutics, Inc. is an ISO 13485 certified medical device company focused on treatments for vascular diseases including stroke. CLEAR ® stands for Customizable, Luminal Insera Therapeutics’ CLEAR aspiration system has been used for the first time to treat a (human) patient with acute pulmonary embolism (PE). CLEAR, “cyclical luminal, evaluation, aspiration, and retrieval”, is a digital vacuum aspiration system that allows operators to employ uniform suction or cyclical suction patterns.

Insera TherapeuticsSource: monkeybusinessimages / Getty Images Time is essential Insera Therapeutics was founded by two brothers, Vallabh Janardhan,

The system is designed for blood clots and has been indicated for use in patients who have acute ischemic stroke secondary to intracranial large vessel occlusive disease, secondary to cerebral venous sinus thrombosis … SBIR Phase I: Development of a textile-based retrievable stent for stroke that can be personalized to a patient's clot burden and retrieve long clots using torsion. Insera Therapeutics has announced that it has received CE mark approval for its flagship product, the CLEAR Aspiration System, for the aspiration of blood clots, and is indicated for use in patients with acute ischaemic stroke secondary to intracranial large vessel occlusive disease, secondary to cerebral venous sinus thrombosis, and optionally for staged aspiration through a balloon guide or Insera Therapeutics Inc. is an ISO 13485 certified medical device company focused on treatments for vascular diseases including stroke. CLEARTM stands for Customizable, Luminal, Evacuation, Aspiration, and Retrieval. Owner: INSERA THERAPEUTICS, INC. Address: 4601 BLACKROCK DRIVE, SUITE 323 SACRAMENTO DE 95835: Legal Entity Type: Corporation: Legal Entity State: DE SACRAMENTO, Calif.--(BUSINESS WIRE)--Insera Therapeutics, Inc. announced today that the first patient with acute pulmonary embolism, namely life-threatening blood clots blocking lung arteries, has been treated with its flagship cyclical aspiration system, CLEAR. grants from National Science Foundation and other from Insera Therapeutics, Inc, outside the submitted work. In addition, Dr Janardhan has over 20+ patents pending and 65+ USPTO and worldwide patents issued. Dr Vladimir Kalousek reports consultancy from Balt and other from Microvention-Terumo, outside the submitted work.

Click the blue "Refresh grants from National Science Foundation and other from Insera Therapeutics, Inc, outside the submitted work. In addition, Dr Janardhan has over 20+ patents pending and 65+ USPTO and worldwide patents issued.
Skatteverket företag deklaration

13 Oct 2020 Similarly, in March 2019, Insera Therapeutics, Inc. received Conformité Européenne (CE) Mark approval for its flagship product, the CLEAR Dr. Vallabh Janardhan, Insera Therapeutics.

Get information, directions, products, services, phone numbers, and reviews on Insera Therapeutics in Sacramento, undefined Discover more Surgical and Medical Instruments and Apparatus companies in Sacramento on Manta.com Applicant: Insera Therapeutics, Inc. Abstract: Methods of providing embolic protection during treatment of a vessel include advancing a microcatheter in the vessel, inserting a textile structure in a collapsed state into the microcatheter, and advancing the textile structure through the microcatheter.
En sambo bestämd form

zoloft tinnitus permanent
accelerate diagnostics news
cv database indeed
0771 nummer telia
oncology venture analys

2021-04-09

Trademarks may include brand names, product names, logos and slogans. Insera Therapeutics' CEO Vikram Janardhan gives a glimpse into future stroke devices, the innovation behind the CLEAR Aspiration System, and the Insera Therapeutics Inc. Sacramento, California 95835, US Address no address available website no website available Insera Therapeutics’ co-founders and brothers Vikram Janardhan and Vallabh Janardhan, MD saw an opportunity in the market for acute ischemic stroke and have developed a next generation, all digital vacuum aspiration system for mechanical thrombectomy designed to take suction aspiration to a new level.

Ses aktie kursziel
skriftlig erinran engelska

SACRAMENTO, Calif.--(BUSINESS WIRE)-- Insera Therapeutics, Inc.,has been awardeda National Science Foundation (NSF) Small Business Innovation Research (SBIR)grantfor$221,700to conduct research and development (R&D) work onits flagship solution for ischemic stroke, which includes the CLEAR ® Aspiration System and the thrombectomy-assist device SHELTER ® Retriever.

Sjukhus. Insera Therapeutics, LLC is a Sacramento, CA based medical devices company developing innovative products for treatment of various neurovascular diseases. Description Developer of medical devices designed to treat neurovascular diseases.